Advertisement

 

 

Research Suggests Potential Key to Alternative Lupus Treatment

Research Suggests Potential Key to Alternative Lupus Treatment
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

THURSDAY, Feb. 16, 2017 (HealthDay News) — In patients with systemic lupus erythematosus (SLE), mitochondrial reactive oxygen species (ROS) induce oligomerization of mitochondrial antiviral signaling (MAVS) protein and type I interferon (IFN) production, according to a study published recently in Science Signaling.

Iwona A. Buskiewicz, Ph.D., from the University of Vermont in Burlington, and colleagues examined virus-independent activation of MAVS protein in patients with SLE.

Noting that MAVS protein usually forms a complex with retinoic acid gene I (RIG-I)-like helicases during viral infection, the researchers found that MAVS protein was activated by oxidative stress, independently of RIG-I helicases. Chemically generated oxidative stress stimulated formation of MAVS oligomers, leading to mitochondrial hyperpolarization and reduced adenosine triphosphate production and spare respiratory capacity; these responses were not seen in cells lacking MAVS that were treated in a similar way. Spontaneous MAVS oligomerization was seen in peripheral blood lymphocytes of SLE patients; this correlated with increased secretion of type I IFN and mitochondrial oxidative stress. MAVS oligomerization and type I IFN production were prevented by inhibition of mitochondrial ROS by the mitochondria-targeted antioxidant MitoQ. In cells expressing the MAVS-C79F variant, which is linked to reduced type I IFN secretion, there was reduced ROS-dependent MAVS oligomerization in plasma versus healthy controls.

“Our findings suggest that oxidative stress-induced MAVS oligomerization in SLE patients may contribute to the type I IFN signature that is characteristic of this syndrome,” the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.
healthday

Submit a Comment

Your email address will not be published. Required fields are marked *

5 × 4 =

[ HIDE/SHOW ]